Basic Search
|
Summaries
|
Advanced SearchViolation Tracker Individual Record
Company: Forest Laboratories LLC
Current Parent Company:
AbbVie
Parent at the Time of the Penalty Announcement:
subscribe to see this data field
Penalty: $750,000,000
Year: 2020
Date: May 27, 2020
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal:
Generic Drug Pay for Delay
Violation Description: Forest Laboratories agreed to pay $750 million to direct purchasers to settle litigation alleging it conspired to block a generic version of the Alzheimer's drug Namenda.
Level of Government: federal
Action Type: private litigation
Court: Southern District of New York
Civil or Criminal Case: civil
Case ID: 1:15cv7488
Case Name: In re Namenda Direct Purchaser Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: Illinois
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data:
(click here)
Link to PACER Case Docket (must be logged in):
(click here)
Link to Archived Court Document:
subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker
Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the
Update Log.